First-Pass Metabolism & Peptide Bioavailability

First-pass metabolism is the primary reason most peptides cannot be taken orally. It refers to the sequential degradation of a drug as it passes through the gastrointestinal tract and liver before reaching systemic circulation. For peptides — which are chains of amino acids — the GI tract is essentially a digestion machine optimized to break them down into absorbable amino acids for nutrition. The same system that efficiently digests dietary protein efficiently destroys therapeutic peptides.

The three barriers

1. Gastric acid and pepsin

The stomach maintains a pH of 1.5–3.5 and contains pepsin, an endopeptidase that cleaves peptide bonds at hydrophobic amino acid residues. Most peptides are denatured by acid and fragmented by pepsin within minutes of oral ingestion.

Notable exception: BPC-157 is unusually acid-stable, derived from a protein found in gastric juice itself. This stability is why oral BPC-157 is considered theoretically viable for GI targets — though formal oral bioavailability data in humans is limited.

2. Intestinal proteases and the brush border

Peptides surviving the stomach encounter pancreatic proteases (trypsin, chymotrypsin, elastase, carboxypeptidases) in the duodenum, followed by membrane-bound peptidases (aminopeptidase N, dipeptidyl peptidase IV) on the intestinal brush border. DPP-IV is particularly relevant for peptide pharmacology — it cleaves GLP-1 at position 2 within minutes, which is why native GLP-1 has a 2-minute half-life.

3. Hepatic first-pass extraction

Any peptide absorbed through the intestinal wall enters the portal circulation and passes through the liver before reaching systemic blood. The liver contains additional proteases and metabolic enzymes that further degrade peptide fragments. Hepatic first-pass extraction can remove 50–90% of absorbed drug.

The combined effect: oral bioavailability for most unmodified peptides is less than 1%. A 5 mg oral dose may deliver less than 50 micrograms to the systemic circulation.

Why this matters for peptide therapy

First-pass metabolism is why most therapeutic peptides are administered by injection (subcutaneous, intramuscular, or intravenous), bypassing the GI tract entirely. It is also why intranasal delivery is preferred for CNS-targeted peptides like Semax and Selank — nasal mucosa absorption avoids both GI degradation and hepatic first-pass.

The delivery route determines:

• Bioavailability: subcutaneous injection typically achieves 65–95% bioavailability vs. <1% oral for unmodified peptides
• Onset: IV is immediate; SC is 15–60 minutes; oral (if viable) is 30–120 minutes
• Patient compliance: oral is preferred by patients; injection is a barrier to adherence
• Cost: lower bioavailability means higher doses are needed, increasing cost per effective dose

Engineering solutions for oral peptides

The pharmaceutical industry has invested heavily in overcoming first-pass metabolism for peptides:

Oral semaglutide (Rybelsus)

The landmark achievement in oral peptide delivery. Rybelsus co-formulates semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), an absorption enhancer that:

1. Locally raises gastric pH, protecting semaglutide from pepsin
2. Promotes transcellular absorption across the gastric epithelium
3. Transiently increases membrane permeability

Even with this engineering, oral semaglutide has only ~1% bioavailability — a 14 mg oral tablet delivers roughly the same exposure as a 1 mg subcutaneous injection. The patient must take it on an empty stomach with minimal water and wait 30 minutes before eating. Despite these constraints, Rybelsus proved that meaningful oral peptide therapy is achievable.

Other approaches

• Protease inhibitors: co-formulating peptides with protease inhibitors (aprotinin, soybean trypsin inhibitor) to reduce enzymatic degradation in the intestine
• Enteric coatings: acid-resistant coatings that dissolve only at intestinal pH, bypassing gastric degradation
• Permeation enhancers: molecules that transiently open tight junctions between intestinal epithelial cells (sodium caprate, chitosan derivatives)
• Nanoparticle encapsulation: polymer or lipid nanoparticles that protect peptides during GI transit and promote transcytosis across the intestinal barrier
• PEGylation and lipidation: attaching polyethylene glycol chains or fatty acids to peptides improves stability and extends half-life (semaglutide's C-18 fatty acid chain also aids albumin binding)

The practical takeaway

When evaluating a peptide product, the administration route should match the pharmacological reality:

• Injectable peptides (most research peptides) bypass first-pass entirely — this is the standard for good reason
• Intranasal peptides (Semax, Selank, oxytocin) avoid GI degradation and may access the CNS directly
• Oral peptide claims should be met with scrutiny unless the formulation specifically addresses acid stability, protease resistance, and absorption enhancement. An oral peptide without these engineering solutions is likely delivering negligible systemic exposure
• Topical peptides (GHK-Cu, Matrixyl in skincare) bypass first-pass by targeting local tissue — bioavailability is limited to the skin, which is the desired target

First-pass metabolism is not a limitation to overcome for its own sake — it is a biological reality that determines which delivery route will actually get a therapeutic peptide to its target.